Sialic acid conjugated cationic nanostructured lipid carriers loaded with natural bioactives for the management of Alzheimer s disease
Loading...
Date
item.page.authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The present research aimed to design and evaluate Myricetin (MY) loaded nanostructured lipid
newlinecarriers (MY-NLCs) to observe the enhancement of the bioavailability in the brain and
newlinecognitive function in Alzheimer s. MY-NLCs were prepared and optimized using central
newlinecomposite design (CCD). In-vitro MTT assay and cellular accumulation were evaluated in SH-
newlineSY5Y neuroblastoma cells. Animals were i.p injected the MYS and MY-NLCs at a dose of 40
newlinemg/kg body weight and MY concentration in brain and plasma were analysed (n=3). Further,
newlinethe pharmacodynamics studies were evaluated in the (Aand#946;1-42) induced Alzheimer s rat model
newline(n=6) and cognitive performance was assessed using Morris water maze (MWM) test followed
newlineby histological and neurotransmitters analyses in rats brain. The optimized MY-NLCs showed
newline89.7±26.0 nm particle size, 80.81±10.39% entrapment efficiency, and 5.08±1.0% of drug
newlineloading capacity. The in-vitro release studies revealed a biphasic release pattern and also
newlinedemonstrated distinct cellular internalization in SH-SY5Y cells. Developed MY-NLCs
newlineexhibited 2.77 folds higher AUC 0-24 in plasma and drug targeting efficiency for MY into the
newlinebrain was found 127.05% as compared to MYS. The mitigating potential of MY-NLCs
newline(10mg/kg) was also observed in behavioural parameters and neurotransmitter levels regulation
newlinein the rat brain. MY-NLCs would be investigated as a potentially promising drug delivery
newlineplatform for a variety of neurodegenerative payloads.
newlineBased on preliminary successful findings, we further develop and evaluate cationic MY
newlinefabricated nanostructured lipid carrier (Cat-MY-NLC) and sialic acid (SA) grafted Sia-Cat-
newlineMY-NLC for Alzheimer s disease (AD) management. After characterization studies, In-vitro
newlinecytotoxicity, cellular uptake, Aand#946; aggregation inhibition and mitochondrial membrane potential
newlineof prepared NLCs were observed in SH-SY5Y cells. The trans- endothelial electrical resistance
newline(TEER) was measured through HCMEC/D3 cells. Finally, the pharmacokinetic and
newlinepharmacodynamic studies were also performed.